CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Decoy Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Decoy Therapeutics Inc
2450 Holcombe Blvd Ste J-608
Phone: (617) 874-1821p:617 874-1821 HOUSTON, TX  77021-2041  United States Ticker: DCOYDCOY
Business Summary
Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202512/31/2024YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board William K.McVicar 67 1/1/2023 4/5/2017
Chief Executive Officer, Director Frederick E.Pierce 64 11/12/2025 11/12/2025
Chief Financial Officer, Executive Vice President Mark J.Rosenblum 72 11/12/2025 9/13/2019
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Flex Innovation Group LLC 800 Boylston Street Boston MA United States

Business Names
Business Name
DCOY
Decoy Therapeutics
Flex Innovation Group LLC
4 additional Business Names available in full report.

General Information
Number of Employees: 2 (As of 3/3/2025)
Outstanding Shares: 6,384,177 (As of 12/26/2025)
Shareholders: 139
Stock Exchange: NASD
Federal Tax Id: 465087339
Fax Number: (302) 655-5049
Email Address: info@flex-pharma.com


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, February 3, 2026